• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Cannabis

Is Psilocybin the New CBD?

As psychedelic medicines begin to become decriminalized, psilocybin seems to be leading the way in this category.
By DEBRA BORCHARDT
Sep 25, 2020 | 03:12 PM EDT
Stocks quotes in this article: LKYSF, MMEDF, LLY

Is psilocybin to psychedelic medicine what CBD is to medical marijuana?

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and psilocin are chemical compounds that come from certain types of dried or fresh hallucinogenic mushrooms found in various parts of the world. There are over 180 different species of mushrooms that contain psilocybin.

As psychedelic medicines begin to become decriminalized, psilocybin seems to be leading the way in this category, which also typically includes Ketamine, MDMA and LSD. Ketamine is an anesthetic that has been approved for use in drug-resistant depression patients. It is classified as a Schedule 3 drug. MDMA is a Schedule 1 drug and is also undergoing research as a treatment for PTSD and depression. LSD is also a Schedule 1 drug and is gaining popularity for small dosage applications to treat depression.

Psilocybin's natural origins make it more desirable versus the chemical psychedelic compounds. It also sounds much less threatening. A cute little mushroom seems less scary that tripping on LSD or taking a hit of ecstasy (MDMA). Even though Ketamine is already being used in clinics to treat patients, the broader market hears the word and thinks of animal tranquilizers and club kids using Special K. However, nature isn't a standardized world and that's where an emerging industry is, dare we say it, growing like mushrooms.

Legal Picture Changing

The legal landscape for psilocybin is rapidly changing. Several municipalities in the United States have decriminalized it including Denver Colo., Oakland and Santa Cruz, Calif. The latest to join this small group is Ann Arbor, Mich.

In Canada, the Canadian Minister of Health has granted a few terminally ill patients legal access to psilocybin to ease their end of life anxiety. So, the legality of these products is moving quickly. That has caused what had been a relatively small group of companies working with psilocybin to become a fast-growing sector of alternative plant medicine brands.

Numinus Wellness

Numinus Wellness Inc. (LKYSF) (TSXV: NUMI) reported this week that it has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7,000 square-foot Health Canada licensed facility. The company wants to be the first to market for product development when it comes to psychedelic-assisted therapy. Its license covers the production and extraction of psilocybin from mushrooms and it hopes to develop standardized methods for extractions.

In addition, the company hopes to explore product formulations of naturally occurring psilocybin and investigate naturally occurring psilocybin's efficacy as an alternative supply to synthetic psilocybin that is currently being used in research.

Ultimately, Numiness wants to use its own products in its own clinics for psilocybin-assisted psychotherapy, as well as other company's clinics.

Mind Medicine

Mind Medicine (MMEDF) also known as MindMed recently applied for an uplisting from the OTC Markets Group to the Nasdaq. The company has been conducting R&D work on psilocybin in collaboration with the University Hospital Basel's Liechti Lab in a study to better understand and compare the altered states of consciousness induced by psilocybin and LSD.

As part of its agreement with the University Hospital Basel, MindMed has noted that it will retain an exclusive license to all IP and any patents generated from data or findings in the study and related work on psilocybin, such as pharmacokinetic data and information on the metabolism. The company said it expects the study to be finished in the second quarter of 2021.

MindMed President Dr. Miri Halperin Wernli said, "Both LSD and psilocybin are thought to induce hallucinations mainly through the stimulation of the 5-HT2A receptor. However, it is known that there are differences in the receptor activation profiles between the two substances and these differences may induce different subjective effects. Therefore, with this study we will try to understand and compare the altered states of consciousness induced by the two substances and identify potential medicines for patients."

Cybin

Even big pharma executives are jumping into the industry. Toronto-based mushroom life sciences company Cybin is a private company that recently named Doug Drysdale as its new CEO. Cybin is currently working on sublingual psilocybin strips and has attracted a number of former big names in Big Pharma who see this as the future of mental healthcare.

Drysdale's journey includes stints at Actavis, Pernix Therapeutics, Tedor Pharma, and Alvogen. Cybin's Chief Medical Officer Jukka Karjalainen also has 25+ years of experience in the pharma sector including Bioavail and Eli Lilly (LLY) .

The FDA has designated psilocybin as a "breakthrough therapy" for treatment-resistant depression. Additional indications are being studied by researchers at NYU and John Hopkins (among other universities) for PTSD, eating disorders, smoking cessation and treatment of substance use disorder.

In Closing

Investors still need to be cautious on companies that are targeting psilocybin products. There are some businesses that are playing up the hype of mushrooms with little to back up their claims.

Also, some companies are claiming to work with mushrooms, but it isn't the psychedelic kind. While that isn't to say there aren't benefits to supplemental products like Lions Mane, it isn't the same as a company focused on psilocybin mushroom products.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider certain of these names to be a small-cap stock. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no positions in any securities mentioned.

TAGS: Investing | Trading | Healthcare | Marijuana | Cannabis

More from Cannabis

Doug Kass: Cannabis Stocks Are Still Not SAFE

Doug Kass
Dec 20, 2022 11:15 AM EST

Though it is tempting, there are a host of reasons why I'm not bottom fishing.

Cannabis ETFs Could Soon Turn a New Leaf

Mark Abssy
Dec 8, 2022 1:11 PM EST

With likely passage of new legislation, the pot industry might have a remedy for the nausea it gave investors.

3 Market Sectors Are Likely to Be Most Impacted by the Midterm Election

James "Rev Shark" DePorre
Nov 8, 2022 6:22 AM EST

The focus is on positioning for the election and CPI Thursday.

I'm Monitoring a Cannabis ETF That's Showing Signs of Bottoming

Bob Byrne
Nov 7, 2022 8:04 AM EST

It's a dicey play as the price action isn't defined as yet and the ETF still could break lower.

If You're High on Tilray, Invest for the Long Term

Stephen Guilfoyle
Oct 7, 2022 11:06 AM EDT

TLRY is probably not that close to sustained profitability, but it has built the balance sheet to tough out these hard times.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:22 AM EST REAL MONEY

    LIVE EVENT: Bruce Kamich and Todd Campbell Share Their Stock Market Insights

    This Monday, Feb. 6 at 12 p.m., our very own exper...
  • 02:58 PM EST REAL MONEY

    Sarge Guilfoyle Breaks Down the Jobs Report, Fed Policy and Stocks!

    Watch it here!
  • 11:35 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading an Irrational Market
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login